Fosavanse

Help protect your post-menopausal patients from osteoporotic fractures
With 5600 IU of Vitamin D

The only osteoporosis therapy with 5600 IU of vitamin D that provides demonstrated fracture prevention at the hip and spine, in one tablet.

---

Campaign files

Brand name: Fosavanse
Generic name/category: Alendronate and colecalciferol
Company: Merck, Sharp & Dohme
Country/Market: Ireland, Europe
Indication(s)/Category: Osteoporotic fracture prevention in post-menopausal women
Target: Healthcare Professionals (HCP)
Tagline: none
Medium: Print ad
Size/duration: Single-page
Publication/Aired:
Hospital Doctor of Ireland - V18 N3 - 2012
Hospital Doctor of Ireland - Volume 18 - Number 4 - 2012
Modern Medicine - V42 N3 - 2012
Hospital Doctor of Ireland - Volume 18 - Number 5 - 2012
Hospital Doctor of Ireland - Volume 18 - Number 10 - December 2012
Modern Medicine - V42 N6 - 2012

To see all of this brand's ads on AdPharm, [url=https://adpharm.net/thumbnails.php?search=Fosavanse"> Campaign files

From Wikipedia:
Alendronic acid (INN) or alendronate sodium (USAN, sold as Fosamax by Merck) is a bisphosphonate drug used for osteoporosis and several other bone diseases. It is marketed alone as well as in combination with vitamin D (2,800 U and 5600 U, under the name Fosamax+D). Merck's U.S. patent on alendronate expired in 2008 and Merck lost a series of appeals to block a generic version of the drug from being certified by the U.S. Food and Drug Administration (FDA).

On February 6, 2008, the US FDA approved the first generic versions of alendronate, which were marketed by Barr Pharmaceuticals and Teva Pharmaceuticals USA. Teva Pharmaceuticals manufactures generic alendronate in 5-milligram, 10-milligram, and 40-milligram daily doses, and in 35-milligram and 70-milligram weekly doses, while Barr made generic alendronate in 70-milligram tablets, which were taken once weekly. [1]Barr pharmaceuticals were subsequently acquired by Teva in July 2008.

More on Wikipedia